The estimated Net Worth of John E Sagartz is at least 10.4 百万$ dollars as of 19 August 2020. John Sagartz owns over 3,733 units of Basis Global Technologies Inc stock worth over 10,426,774$ and over the last 6 years he sold BASI stock worth over 0$. In addition, he makes 0$ as Chief Strategy Officer、 Director at Basis Global Technologies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Sagartz BASI stock SEC Form 4 insiders trading
John has made over 2 trades of the Basis Global Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,733 units of BASI stock worth 17,732$ on 19 August 2020.
The largest trade he's ever made was buying 3,733 units of Basis Global Technologies Inc stock on 19 August 2020 worth over 17,732$. On average, John trades about 1,027 units every 105 days since 2019. As of 19 August 2020 he still owns at least 634,232 units of Basis Global Technologies Inc stock.
You can see the complete history of John Sagartz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Sagartz biography
Dr. John E. Sagartz is Chief Strategy Officer, Director of the Company. Dr. Sagartz is an adjunct associate professor of Comparative Medicine at St. Louis University's College of Medicine and serves on the Board of Directors of the Missouri Biotechnology Association. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.
What's John Sagartz's mailing address?
John's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906-1382.
Insiders trading at Basis Global Technologies Inc
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over 266,443$ worth of Basis Global Technologies Inc stock and bought 540,162 units worth 1,698,287$ . The most active insiders traders include Jacqueline M Lemke、Robert Jr. Leasure、William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of 128,544$. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth 88,500$.
What does Basis Global Technologies Inc's logo look like?
Complete history of John Sagartz stock trades at Basis Global Technologies Inc
Basis Global Technologies Inc executives and stock owners
Basis Global Technologies Inc executives and other stock owners filed with the SEC include:
-
Wendy Perrow,
Independent Director -
R. Matthew Neff,
Independent Director -
Richard Johnson,
Independent Director -
Joseph Flynn,
Chief Commercial Officer -
John Sagartz,
Chief Strategy Officer, Director -
Connie Dougherty,
Vice President - Business Development -
I.M. Grossi,
Vice President - Toxicology -
Philip Downing,
Vice President - Preclinical Services -
Andrew Alexander,
Vice President - Pharmacology and Toxicology Operations -
Michael Baim,
Vice President - Bioanalytical Operations -
Beth Taylor,
Chief Financial Officer, Vice President - Finance -
Robert Leasure,
President, Chief Executive Officer, Director -
Gregory Davis,
Interim Chairman of the Board -
Jill Blumhoff,
VP, Finance & CFO -
John P Devine,
VP--Toxicology -
James Sevall Bourdage,
VP, Bioanalytical Services -
Jacqueline M Lemke,
CFO & Vice President--Finance -
Jeffrey Potrzebowski,
VP, Finance & CFO -
John Gregory Beattie,
Chief Operating Officer -
Peterkissinger Candice B Ki...,
-
Daniel Thomas Oakley,
Chief Operating Officer -
Kimberly L Sagartz,
10% owner -
Chrysalis, Llc Sw,
10% owner -
Lori Payne,
VP Bioanalytical Services -
Larry Steven Boulet,
Director -
David W Crabb,
Director -
John B. Landis,
Director -
David L Omachinski,
Director -
Anthony S Chilton,
COO, Scientific Studies -
A. Charlene Sullivan,
Director -
Alberto F Jr Hidalgo,
VP, Bus. Development & Mrkting -
Leslie B Daniels,
Director -
Kathleen Hodges,
Vice President of Quality -
Lina L Reeves Kerner,
V.P. - Human Resources -
Richard M Shepperd,
President & Chief Exec. Off. -
Ronald E Shoup,
Chief Operating Officer -
Craig S Bruntlett,
Sr. V.P. International Sales -
Jon Brewer,
VP Sales/Marketing -
William E Baitinger,
Director -
Candice B Kissinger,
Vice President -
Margaret B Mcclure,
Dir, Pharmaceutical Lab. Div. -
Michael R Cox,
V.P. Finance, CFO -
Emilio Cordova,
V.P. of Business Development -
Edward Chait,
Executive Vice President -
Gerry Henningsen,
Director BAS Evansville -
Donnie A Evans,
Vice President Engineering -
Garyl W Doster,
Director -
Michael P Silvon,
Vice President -
Michael S Noone,
Dir. of Clinical Affairs, Balt -
William Sawyers,
Laboratory Director -
William D Pitchford,
Chief HR Officer